108 related articles for article (PubMed ID: 38475919)
21. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
[TBL] [Abstract][Full Text] [Related]
22. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
[TBL] [Abstract][Full Text] [Related]
24. Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Dhakal P; Bates M; Tomasson MH; Sutamtewagul G; Dupuy A; Bhatt VR
Blood Rev; 2023 May; 59():101036. PubMed ID: 36549969
[TBL] [Abstract][Full Text] [Related]
25. The path to venetoclax resistance is paved with mutations, metabolism, and more.
Sullivan GP; Flanagan L; Rodrigues DA; Ní Chonghaile T
Sci Transl Med; 2022 Dec; 14(674):eabo6891. PubMed ID: 36475901
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Wang X; Hu R; Song Z; Zhao H; Pan Z; Feng Y; Yu Y; Han Q; Zhang J
Cancer Lett; 2022 Oct; 547():215880. PubMed ID: 35981569
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H; Wei AH; Appelbaum FR; Craddock C; DiNardo CD; Dombret H; Ebert BL; Fenaux P; Godley LA; Hasserjian RP; Larson RA; Levine RL; Miyazaki Y; Niederwieser D; Ossenkoppele G; Röllig C; Sierra J; Stein EM; Tallman MS; Tien HF; Wang J; Wierzbowska A; Löwenberg B
Blood; 2022 Sep; 140(12):1345-1377. PubMed ID: 35797463
[TBL] [Abstract][Full Text] [Related]
28.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
29. Advances in acute myeloid leukemia.
Newell LF; Cook RJ
BMJ; 2021 Oct; 375():n2026. PubMed ID: 34615640
[TBL] [Abstract][Full Text] [Related]
30. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
Taube F; Georgi JA; Kramer M; Stasik S; Middeke JM; Röllig C; Krug U; Krämer A; Scholl S; Hochhaus A; Brümmendorf TH; Naumann R; Petzold A; Mulet-Lazaro R; Valk PJM; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Herold S; Stölzel F; Sockel K; von Bonin M; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
Blood; 2022 Jan; 139(1):87-103. PubMed ID: 34320176
[TBL] [Abstract][Full Text] [Related]
31. Novel insights of acute myeloid leukemia with CEBPA deregulation: Heterogeneity dissection and re-stratification.
Nie Y; Su L; Li W; Gao S
Crit Rev Oncol Hematol; 2021 Jul; 163():103379. PubMed ID: 34087345
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
33. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
34. ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?
Féral K; Jaud M; Philippe C; Di Bella D; Pyronnet S; Rouault-Pierre K; Mazzolini L; Touriol C
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33573353
[TBL] [Abstract][Full Text] [Related]
35. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
Zhang H; Nakauchi Y; Köhnke T; Stafford M; Bottomly D; Thomas R; Wilmot B; McWeeney SK; Majeti R; Tyner JW
Nat Cancer; 2020 Aug; 1(8):826-839. PubMed ID: 33123685
[TBL] [Abstract][Full Text] [Related]
37. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Jones CL; Stevens BM; Pollyea DA; Culp-Hill R; Reisz JA; Nemkov T; Gehrke S; Gamboni F; Krug A; Winters A; Pei S; Gustafson A; Ye H; Inguva A; Amaya M; Minhajuddin M; Abbott D; Becker MW; DeGregori J; Smith CA; D'Alessandro A; Jordan CT
Cell Stem Cell; 2020 Nov; 27(5):748-764.e4. PubMed ID: 32822582
[TBL] [Abstract][Full Text] [Related]
38. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
39. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options.
Wu X; Luo Q; Liu Z
Cell Death Dis; 2020 Jul; 11(7):556. PubMed ID: 32699213
[TBL] [Abstract][Full Text] [Related]
40. The "Janus" Role of C/EBPs Family Members in Cancer Progression.
Tolomeo M; Grimaudo S
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
